Answer:
Firm A will buy all of the firm B's pollution permits. Each one will cost between $100 and $200.
Explanation:
The firm B will gain from the trade of pollution permits. Firm A will need higher pollution permits since it emits 100 tons of chemicals into air and the cost for eliminating each ton is $200. This cost is higher than the cost to Firm B which is $100 only. Firm A will buy all the pollution permits from Firm B and there will advantage for the Firm B to gain from the trade.
Answer:
a. $29,496
b. $21,996
Explanation:
a. The Computation of budgeted marketing expense for the fourth quarter is shown below:-
Sales units 2,640
(2400 × 110%)
Variable marketing expenses per unit sold $0.15
Total Variable marketing expenses $396
Fixed Marketing expenses $18,000
Salaries ($6,000 × 3)
Depreciation ($2,500 × 3) $7,500
Insurance ($1,200 × 3) $3,600
Total Fixed marketing expenses $29,100
Budgeted marketing expense
for the fourth quarter $29,496
b. Estimated cash payment for marketing expenses for the fourth quarter = Budgeted marketing expense for the fourth quarter - Depreciation
= $29,496 - $$7500
= $21,996
The answer should be c͟o͟m͟m͟u͟n͟i͟c͟a͟t͟i͟o͟n͟, but this question seems a bit vague.
Answer:
Located at the Monsanto's world headquarters, the Nidus Center is a unique Non-profit Incubator facility.
Explanation:
Mosanto was founded in 1901 as an agrochemicals and agricultural biotechnology corporation.
The Nidus Center, on the Monsanto campus, 893 N. Warson Road, is funded by Monsanto but governed by an independent board.
The Nidus Center for Scientific Enterprise, a nonprofit incubator for plant and life sciences companies, secured its first start-up business known as GenChemiCs.
GenChemiCs, which designs and improves chemical compounds using cutting-edge, computer-based technologies, moved in March 2000. It was founded by University of Missouri-St. Louis Professor William Welsh, who is a Professor of Chemistry.
The start-up also does business with a number of large companies, including Monsanto, Mallinckrodt, Searle and London-based AstraZeneca.
